<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="370492">
  <stage>Registered</stage>
  <submitdate>26/05/2016</submitdate>
  <approvaldate>2/06/2016</approvaldate>
  <actrnumber>ACTRN12616000726459</actrnumber>
  <trial_identification>
    <studytitle>A randomised trial of krill oil for osteoarthritis of the knee </studytitle>
    <scientifictitle>A randomised placebo controlled trial to evaluate the effect of krill oil on pain and effusion size in patients with knee osteoarthritis</scientifictitle>
    <utrn>U1111-1181-7087</utrn>
    <trialacronym>KARAOKE Trial</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>130 patients with clinical knee osteoarthritis, significant knee pain and effusion on imaging will receive 2g (2 capsules of 1 g each) of krill oil per day for 24 weeks. Adherence to treatment will be monitored by counting the return capsules at 12 and 24 week visits.</interventions>
    <comparator>130 patients with clinical knee osteoarthritis, significant knee pain and effusion on imaging will receive 2g (2 capsules of 1 g each) of placebo (microcrystalline cellulose) per day for 24 weeks. Adherence to treatment will be monitored by counting the return capsules at 12 and 24 week visits.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in knee pain (assessed by 100mm VAS) over 24 weeks in patients with clinical knee OA, significant knee pain and effusions.</outcome>
      <timepoint>Mixed model accounting for overall pain at baseline, 4, 12, 16, 20 and 24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in effusion size from baseline to 24 weeks measured using MRI quantitative measurements in patients with symptomatic OA of the knee and knee effusion.
</outcome>
      <timepoint>Baseline and 24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in knee pain from baseline to each of the following visits at 4, 8, 12, 16, 20 and 24 weeks (assessed by 100mm VAS) in patients with clinical knee OA and effusion.</outcome>
      <timepoint>Linear regression using change in knee pain from baseline to each time point (4, 8, 12, 16, 20 and 24 weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in WOMAC knee pain (total, weight bearing and non-weight bearing) from baseline to 4, 8, 12, 16, 20, and 24 weeks in patients with clinical knee OA, significant knee pain and effusions.</outcome>
      <timepoint>baseline and 4, 8, 12, 16, 20 and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in effusion-synovitis score (assessed using modified WORMS semi-quantitative scoring system) from baseline to 24 weeks in patients with clinical knee OA, significant knee pain and effusions.</outcome>
      <timepoint>baseline and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in bone marrow lesion size (assessed using MRI semi-quantitative and quantitative methods) from baseline to 24 weeks in patients with clinical knee OA, significant knee pain and effusions.</outcome>
      <timepoint>baseline and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in hand pain (assessed by 100mm VAS) from baseline to 4, 8, 12, 16, 20, and 24 weeks in patients with clinical knee OA, significant knee pain and effusions.</outcome>
      <timepoint>baseline and 4, 8, 12, 16, 20 and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in WOMAC knee function (assessed by WOMAC scoring system) from baseline to 4, 8, 12, 16, 20 and 24 weeks in patients with clinical knee OA, significant knee pain and effusions.</outcome>
      <timepoint>baseline and 4, 8, 12, 16, 20 and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>OMERACT-OARSI responders at 4, 8, 12, 16, 20 and  24 weeks in patients with clinical knee OA, significant knee pain and effusions.</outcome>
      <timepoint>4,8,12,16,20 and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in CRP (assessed as hsCRP from serum assay) from baseline in patients with clinical knee OA, significant knee pain and effusions.</outcome>
      <timepoint>Baseline, 12 and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in blood lipids from baseline in patients with clinical knee OA, significant knee pain and effusions</outcome>
      <timepoint>Baseline, 12 and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in leg muscle strength (assessed by dynamometer) from baseline to 12, and 24 weeks in patients with clinical knee OA, significant knee pain and effusions.</outcome>
      <timepoint>baseline and 12, and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in analgesic use (assessed using the questionnaire designed for this study) from baseline to 12, and 24 weeks in patients with clinical knee OA, significant knee pain and effusions.</outcome>
      <timepoint>Baseline, 12, and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in quality of life (assessed by AQoL-6D) from baseline to 12 and 24 weeks in patients with clinical knee OA, significant knee pain and effusions.</outcome>
      <timepoint>Baseline, 12 and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety (assessed by recording any new symptoms, changes in medications and hospital admissions) of treatment and placebo will be assessed over 24 weeks in patients with clinical knee OA, significant knee pain and effusions.

Krill oil is a very safe medication, with few known side effects.  
1. Krill oil may reduce insulin sensitivity by a small amount, although whether this would be large enough to make a difference to blood sugar control in people with diabetes is not clear.  However, if the participant has diabetes, they will be advised to discuss this with the study doctor and their GP before starting the study. We will be collecting the fasting blood glucose levels at baseline and 12 weeks and any incident diagnosis will be recorded in the medications and safety questionnaire forms.

2. Krill oil is not suitable for people who already use anticoagulants (eg warfarin), high dose aspirin or non-steroidal antiinflammatory drugs (NSAIDs).  If they are already using these medications, they will be excluded. Incident medical conditions and the use of these medications will be recorded in the medications and safety questionnaire forms.

3. Krill oil is not suitable for people who have allergies to seafood, and they will be excluded. Any incident allergic reaction will be recorded as new symptoms using the medications and safety questionnaire forms.</outcome>
      <timepoint>4, 8, 12, 16, 20 and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in T2 map values (assessed using non-contrast compositional MRI) from baseline to 24 weeks in patients with clinical knee OA, significant knee pain and effusions.</outcome>
      <timepoint>baseline and 24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	Aged over 40 years old.
2.	Men and women with significant knee pain on most days (defined as a VAS &gt;40mm).
3.	Knee effusionsynovitis on MRI:  In TASOAC study the proportion of participants who had effusionsynovitis on MRI was high (67%), suggesting that localised knee inflammation is common and that MRI is an appropriate screening tool.
4.	Meet American College of Rheumatology (ACR) clinical criteria for knee OA confirmed by a rheumatologist.  
</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	Inability to have an MRI (claustrophobia, metal in eyes or selected knee, pacemakers).
2.	Severe knee OA (joint space narrowing (JSN) on X-ray of Grade 3 using the Osteoarthritis Research Society International (OARSI) atlas).
3.	Use of anticoagulants, high dose aspirin or non-steroidal antiinflammatory drugs (NSAIDs), as krill oil is contraindicated in such people.
4.	Unwillingness to stop taking krill oil and fish oil medications 30 days prior to the trial and during the trial.
5.	Other forms of inflammatory arthritis (especially rheumatoid arthritis and gout).
6.	Seafood allergy.
7.	Significant knee injury within the last 6 months.
8.	Arthroscopy or open surgery in the index knee in the last 12 months, or planned.
9.	Injections of corticosteroids (last 3 months) or hyaluronic acid (last 6 months) in the index knee.
10.	Pregnancy or breastfeeding.
11.	Use of any investigational drug(s) and/or devices within 30 days prior to randomisation
12.	Presence of any serious medical illness that may preclude 24 week follow up.
13.	Inability to provide informed consent.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by computer</concealment>
    <sequence>Simple randomisation using a randomisation table created by computer software</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Visual Analog Scale knee pain scores and WOMAC scores will be analyzed using a repeated-measures mixed model with terms for age, sex, body mass index (calculated as weight in kilograms divided by height in meters squared), treatment, week, and trial center. The correlation within the repeated measures will be addressed by using an individual participant identification as a random effect. The effect of treatment will be  evaluated by the month Ã— treatment interaction. 

Linear regression will be used to compare changes in maximal effusion size and function in univariate and multivariable modelling (if groups are not well matched at baseline) between groups using intention to treat analysis for all outcomes. Per protocol analyses will be completed for study participants consuming &gt;=80% of capsules. Significance will be p &lt; 0.05 (two tailed). Missing data will be accounted for by using propensity weighting, as appropriate.

Based on inhouse data, assuming 10mm difference between krill oil and placebo on the VAS pain scale (reduction in VAS pain scores in the placebo group by -15.5 +/- 25.5 mm over 12 weeks), 90% power, and 5% probability of type 1 error (alpha=0.05), we will need 234 participants. Adjusting for 10% loss to follow up, we need 260 participants (130 in each arm). Based on data from Tasmanian Older Adult Cohort (TASOAC) and Vitamin D Effects on Osteoarthritis (VIDEO) trial , this will give us 96% power to detect a difference in effusion size of 20% (mean 2.24cm2, SD of change 1.35). </statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>20/06/2016</anticipatedstartdate>
    <actualstartdate>6/12/2016</actualstartdate>
    <anticipatedenddate>1/11/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>260</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,TAS,WA,VIC</recruitmentstate>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>The Alfred - Prahran </hospital>
    <hospital>The Queen Elizabeth Hospital - Woodville</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Fiona Stanley Hospital - Murdoch</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Tasmania</primarysponsorname>
    <primarysponsoraddress>Menzies Institute for Medical Research
17 Liverpool street
Hobart
Tasmania 7000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council Australia</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Tasmanian Community Fund</fundingname>
      <fundingaddress>Tasmanian Community Fund
GPO Box 1350
HOBART TAS 7001</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Graeme Jones</sponsorname>
      <sponsoraddress>Menzies Institute for Medical Research
17 Liverpool Street
Hobart
Tasmania 7000</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Background: Knee osteoarthritis (OA) is a significant and increasing cause of pain and disability in the Australian population. So far, interventions aimed at structural modification have been disappointing. OA affects the whole joint, and inflammation of the joint lining (synovitis and joint fluid) is now recognised as a key part of OA.

Animal studies suggest that krill oil is antiinflammatory. Pilot data in humans shows that krill oil reduces knee pain and systemic inflammation after 30 days, suggesting that an approach targeted at specific mechanisms of disease may be effective for OA. However, this study was of short duration, did not collect any data on structural factors, and included patients with a variety of disorders.  Longer, larger follow up studies are required.

Aim: To compare, using a randomised, placebocontrolled doubleblind design over six months,  the efficacy of krill oil vs identical placebo to treat knee osteoarthritis (OA) (both pain and structure) in 260 patients with clinical knee OA, significant knee pain and effusion on imaging.

Primary hypothesis:
1) Krill oil decreases pain (assessed by 100mm VAS) by 10mm more than identical placebo over 24 weeks in patients with clinical knee OA, significant knee pain and effusions.
2) Krill oil decreases effusion size by 20% over 24 weeks in patients with symptomatic OA of the knee and knee effusion.

Significance and Innovation: If krill oil can both improve symptoms and decrease effusion in OA it has the potential to slow progression to joint replacement. The proposed study represents an innovative approach to this and lends itself to easy implementation as krill oil is already available overthecounter in Australian pharmacies. 
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Tasmania Health &amp; Medical Human Research Ethics Committee (EC00337)</ethicname>
      <ethicaddress>Sarah Day
Menzies Institute for Medical Research
University of Tasmania
17 Liverpool Street
Hobart
Tasmania 7000</ethicaddress>
      <ethicapprovaldate>7/03/2016</ethicapprovaldate>
      <hrec>H0015465</hrec>
      <ethicsubmitdate>15/12/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Graeme Jones</name>
      <address>Menzies Institute for Medical Research
17 Liverpool Street
Hobart
Tasmania 7000</address>
      <phone>+61 3 6226 7705</phone>
      <fax />
      <email>Graeme.Jones@utas.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Laura Laslett</name>
      <address>Menzies Institute for Medical Research
17 Liverpool Street
Hobart
Tasmania 7000</address>
      <phone>+61 417 865 075</phone>
      <fax />
      <email>Laura.Laslett@utas.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Graeme Jones</name>
      <address>Menzies Institute for Medical Research
17 Liverpool Street
Hobart
Tasmania 7000</address>
      <phone>+61 3 6226 7705</phone>
      <fax />
      <email>Graeme.Jones@utas.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Benny Antony</name>
      <address>Menzies Institute for Medical Research
17 Liverpool Street
Hobart
Tasmania 7000</address>
      <phone>+61 421 825 573</phone>
      <fax />
      <email>Benny.EathakkattuAntony@utas.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>